measurable residual disease

Tailoring Transplant Conditioning and Maintenance Therapy in FLT3-ITD AML: Insights on NPM1 Mutations and Measurable Residual Disease

By MedXY 11/04/2025

Posttransplant gilteritinib greatly benefits FLT3-ITD AML patients with NPM1 comutations, while myeloablative conditioning offers limited advantages over reduced-intensity conditioning in eradicating measurable residual disease.

Hematology-Oncology news Pediatrics

Molecular Monitoring of MRD in Pediatric AML with KMT2A::MLLT10: Prognostic Insights and Clinical Impact

By MedXY 10/14/2025

MRD monitoring by RT-qPCR in pediatric AML with KMT2A::MLLT10 fusion identifies patients at high risk despite morphologic remission, informing prognosis and guiding therapy.

Clinical Updates Hematology-Oncology news

Advancing Chronic Lymphocytic Leukemia Management: The Impact of Measurable Residual Disease-Guided Ibrutinib-Venetoclax Therapy

By MedXY 09/26/2025

Phase 3 trial data demonstrate that ibrutinib-venetoclax therapy achieves superior undetectable measurable residual disease rates and significantly prolonged progression-free survival compared with ibrutinib alone or FCR in chronic lymphocytic leukemia.

Clinical Updates Hematology-Oncology Medical News Specialties

MRD-Guided Consolidation Therapy in Newly Diagnosed Multiple Myeloma: Insights from the MIDAS Phase 3 Trial

By MedXY 07/31/2025

MRD-guided consolidation strategies in transplant-eligible multiple myeloma patients did not significantly improve deep remission rates over conventional approaches, questioning the clinical utility of MRD-adapted intensification.